Market Size - US: $50 million (Operating Room segment)
Worldwide: $100 million
Our independent lab compared our product, Stayzon + Bacitracin, to the market leader Bacitracin Ointment. In vitro results showed Stayzon + Bacitracin provided a superior barrier to bacterial growth compared to Bacitracin Oointment. Stayzon + Bacitracin is the only product in the world that keeps a bandage in place and delivers antibiotic to protect the surgical site area.
Results expressed as breakthrough growth under skin (g) or no breakthrough
growth (0)
Test Agent |
Microorganism |
Replicates |
|||||
1 |
2 |
3 |
4 |
5 |
6 |
||
Stayzon |
Staphylococcus aureus |
0 |
0 |
0 |
g |
0 |
0 |
Staphylococcus epidermidis |
0 |
0 |
0 |
0 |
0 |
0 |
|
Enterococcus faecalis |
0 |
0 |
0 |
0 |
0 |
0 |
|
Streptococcus pyogenes |
0 |
0 |
0 |
0 |
0 |
0 |
|
Bacitracin |
Staphylococcus aureus |
0 |
g |
g |
0 |
g |
g |
Staphylococcus epidermidis |
0 |
0 |
g |
0 |
0 |
g |
|
Enterococcus faecalis |
g |
g |
0 |
g |
g |
0 |
|
Streptococcus pyogenes |
0 |
g |
0 |
g |
g |
0 |
|
Mastisol |
Staphylococcus aureus |
g |
g |
g |
g |
g |
g |
Staphylococcus epidermidis |
g |
g |
g |
g |
g |
g |
|
Enterococcus faecalis |
g |
g |
g |
g |
0 |
g |
|
Streptococcus pyogenes |
g |
0 |
g |
g |
g |
g |
|
75% |
Staphylococcus aureus |
g |
g |
g |
g |
g |
g |
Staphylococcus epidermidis |
g |
g |
g |
g |
g |
g |
|
Enterococcus faecalis |
g |
g |
g |
g |
g |
g |
|
Streptococcus pyogenes |
g |
g |
g |
g |
g |
g |
|
Product Licensed - July 2006
